VISHEE(SH:688580)2022-08-28 16:00Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 20%[1]. - The company's operating revenue for the first half of 2022 was CNY 134.13 million, a decrease of 29.94% compared to the same period last year[19]. - Net profit attributable to shareholders for the same period was CNY 38.26 million, down 44.70% year-on-year[19]. - The net profit after deducting non-recurring gains and losses was CNY 27.04 million, a decline of 53.09% compared to the previous year[19]. - Basic earnings per share decreased to CNY 0.5601, down 44.67% from CNY 1.0122 in the same period last year[20]. - The company achieved total operating revenue of 134.13 million yuan, a year-on-year decrease of 29.94%[92]. - The company reported a total revenue of 10,427.81 million RMB for the first half of 2022, an increase from 8,367.70 million RMB in the same period last year[65]. - The company reported a net profit margin of 12% for the first half of 2022, an increase from 10% in the same period last year[120]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching a total of 500,000 users by June 30, 2022[1]. - User data showed a growth of 25% in active users, reaching 5 million by the end of June 2022[117]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[1]. - Market expansion plans include entering two new international markets by Q4 2022, which are projected to add 300 million in annual revenue[120]. Product Development and Innovation - New product development includes the launch of a rehabilitation robot, which is projected to contribute RMB 30 million in revenue by the end of 2022[1]. - The introduction of new products such as MyOnyx and MyoTrac series, which are marketed as biofeedback devices, is expected to enhance the company's market position[11]. - The company has launched multiple rehabilitation robot products, including X-walk100, X-walk200/300, and X-locom100, with X-walk400 in the registration phase and X-locom200/300 preparing for market entry[27]. - The company has developed a compact high-pressure medical power supply for magnetic stimulation products, achieving continuous output requirements of 100Hz pulse frequency and 6Tesla magnetic field strength[49]. - The company has completed the development of a prototype for a magnetic stimulation system aimed at depression, with ongoing work on automatic detection algorithms and clinical validation[60]. Research and Development - The company has invested RMB 5 million in R&D for new technologies in rehabilitation medical devices[1]. - Research and development expenses accounted for 24.43% of operating revenue, an increase of 9.74 percentage points year-on-year[20]. - The total R&D investment amounted to ¥32,762,412.42, an increase of 16.51% compared to the previous year, with the proportion of R&D investment to operating income rising to 24.43%, up by 9.74 percentage points[58]. - The R&D personnel count increased to 172, representing 27.09% of the total workforce, compared to 151 and 26.92% in the previous year[69]. Strategic Initiatives - A strategic acquisition of a local competitor is in progress, which is expected to enhance the company's product offerings and increase market penetration[1]. - The company is actively pursuing international patent applications under the Patent Cooperation Treaty (PCT) to protect its innovative technologies[11]. - The company aims to enhance its operational efficiency through potential mergers and acquisitions in the healthcare technology space[10]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 250 million allocated for potential deals in 2022[120]. Financial Guidance and Future Outlook - The company has provided a performance guidance for the second half of 2022, expecting a revenue growth of 25% compared to the first half[1]. - Future outlook includes a strategic emphasis on developing new technologies to address cognitive function disorders and neonatal brain injuries[11]. - The financial guidance for the upcoming quarters indicates a projected revenue growth of approximately 15% year-over-year, driven by new product launches and market expansion efforts[12]. - The company provided guidance for the second half of 2022, expecting revenue to reach between 1.5 billion and 1.7 billion, which would represent a growth of 20% to 30% compared to the same period last year[120]. Risk Management - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company is closely monitoring industry policies and macroeconomic conditions to mitigate potential risks[90][91]. Compliance and Governance - The company has ensured compliance with all commitments made during the reporting period, with no noted failures to fulfill these commitments[115]. - The company commits to strictly adhere to the "Stabilization Plan for Stock Prices" as per relevant regulations, ensuring all obligations are fulfilled[149]. - The company guarantees that all information submitted to the China Securities Regulatory Commission and the Shanghai Stock Exchange is accurate and complete, taking legal responsibility for any misrepresentation[180].